**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/331

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | EFAVIRENZ TABLETS 600 mg | | **REF. NO: NDQB201610190** |
| **DATE RECEIVED:** 25.10.2016 | **LABEL CLAIM:** | Each film coated tablet contains: Efavirenz USP 600 mg. | |
| **BATCH NO.:** BEA8609A | **PRESENTATION:** | Tan coloured, caplet shaped, biconvex faced tablets, imprinted™ on one face and plain on the other, packed in a white, plastic multi-dose container of 30 tablets in a printed box. | |
| **MFG. DATE:** Apr. 2016 | **MANUFACTURER:** | MACLEODS Pharmaceuticals Ltd. | |
| **EXP. DATE:**  Mar. 2019 | **ADDRESS:** | Village Theda, P.O. Lodhimajra, Tehsil Baddi, Dist. Solan, Himachal Pradesh, 174101, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Kenya Medical Supplies Authority, P. O. Box 47715 - 00100, Nairobi, KENYA. | |
| EFV/12/10/2016/203 | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPENDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App. XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted InHouse Method | RT of the major peak in the assay sample preparation corresponds to that in the assay standard preparation | Super-imposable peak at RT 7.8 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted InHouse Method | No tablet less than 80.0% | 95.5%, (Range | **COMPLIES** |
| **Dissolution** |  |  |  | 94 - 97%) (RSD=1.2%; n=6) |  |
| **Assay** | HPLC | Adopted InHouse Method | 90.0 - 110.0% | 101.0% (RSD=1.2%; n=7) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | SARAH KARIUKI | .......................................................... | DATE: 10-26-2016 |
| **REVIEWER** | DR. GEORGE WANG'ANG'A | .......................................................... | DATE: 30-11-2016 |
| **ANALYST:** | NICHOLAS MWAURA | .......................................................... | DATE: 11-30-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 12-02-2016 |